[HTML][HTML] Natural products modulate NLRP3 in ulcerative colitis
JC Xue, S Yuan, XT Hou, H Meng, BH Liu… - Frontiers in …, 2023 - frontiersin.org
Ulcerative colitis (UC) is a clinically common, progressive, devastating, chronic inflammatory
disease of the intestine that is recurrent and difficult to treat. Nod-like receptor protein 3 …
disease of the intestine that is recurrent and difficult to treat. Nod-like receptor protein 3 …
[HTML][HTML] Medicinal plants, phytochemicals and regulation of the NLRP3 inflammasome in inflammatory bowel diseases: A comprehensive review
R Direito, SM Barbalho, ME Figueira, G Minniti… - Metabolites, 2023 - mdpi.com
Ongoing research explores the underlying causes of ulcerative colitis and Crohn's disease.
Many experts suggest that dysbiosis in the gut microbiota and genetic, immunological, and …
Many experts suggest that dysbiosis in the gut microbiota and genetic, immunological, and …
Biological functions of NLRP3 inflammasome: A therapeutic target in inflammatory bowel disease
Y Song, Y Zhao, Y Ma, Z Wang, L Rong, B Wang… - Cytokine & Growth …, 2021 - Elsevier
Cases of inflammatory bowel disease (IBD), a debilitating intestinal disorder with complex
pathological mechanisms, have been increasing in recent years, straining the capacity of …
pathological mechanisms, have been increasing in recent years, straining the capacity of …
NLRP3: a promising therapeutic target for inflammatory bowel disease
J Zhang, S Zeng, P Wang, Y Chen… - Current Drug Targets, 2023 - ingentaconnect.com
Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is
an intestinal disease with complicated pathological mechanisms. The incidence of IBD has …
an intestinal disease with complicated pathological mechanisms. The incidence of IBD has …
[HTML][HTML] Inflammasome-targeting natural compounds in inflammatory bowel disease: Mechanisms and therapeutic potential
Q Xu, W Sun, J Zhang, Y Mei, J Bao, S Hou… - Frontiers in …, 2022 - frontiersin.org
Inflammatory bowel disease (IBD), mainly including Crohn's disease and ulcerative colitis,
seriously affects human health and causes substantial social and economic burden. The …
seriously affects human health and causes substantial social and economic burden. The …
[HTML][HTML] Therapeutic interventions target the NLRP3 inflammasome in ulcerative colitis: Comprehensive study
One of the significant health issues in the world is the prevalence of ulcerative colitis (UC).
UC is a chronic disorder that mainly affects the colon, beginning with the rectum, and can …
UC is a chronic disorder that mainly affects the colon, beginning with the rectum, and can …
Natural products: experimental efficient agents for inflammatory bowel disease therapy
F Cao, J Liu, BX Sha, HF Pan - Current pharmaceutical design, 2019 - ingentaconnect.com
Inflammatory bowel disease (IBD) is a chronic, elusive disorder resulting in relapsing
inflammation of intestine with incompletely elucidated etiology, whose two representative …
inflammation of intestine with incompletely elucidated etiology, whose two representative …
[HTML][HTML] Oroxylin A inhibits colitis by inactivating NLRP3 inflammasome
W Zhou, X Liu, X Zhang, J Tang, Z Li, Q Wang, R Hu - Oncotarget, 2017 - ncbi.nlm.nih.gov
NLRP3 inflammasome is a novel therapeutic target for inflammatory bowel disease (IBD).
The aim of this study was to investigate the anti-inflammatory effect of a bioactive flavonoid …
The aim of this study was to investigate the anti-inflammatory effect of a bioactive flavonoid …
[HTML][HTML] Inhibition of NLRP3 attenuates sodium dextran sulfate-induced inflammatory bowel disease through gut microbiota regulation
SL Wang, MM Zhang, H Zhou, GQ Su, Y Ding, GH Xu… - biomedical …, 2023 - Elsevier
Background Inflammatory bowel disease (IBD) is a chronic, life-threatening inflammatory
disease of gastrointestinal tissue characterized by inflammation of the gut. Recent studies …
disease of gastrointestinal tissue characterized by inflammation of the gut. Recent studies …
NLRP3 inhibitors as potential therapeutic agents for treatment of inflammatory bowel disease
A Promoda Perera, D Kunde… - Current Pharmaceutical …, 2017 - ingentaconnect.com
Background: Inflammatory bowel disease (IBD) is a group of intestinal disorders
characterised by chronic relapsing inflammation of the small intestine and colon. IBD …
characterised by chronic relapsing inflammation of the small intestine and colon. IBD …